Intellia Therapeutics: Buy Rating Affirmed on Promising NTLA-2001 Data and Upcoming Catalysts
Analyst Terence Flynn from Morgan Stanley maintained a Buy rating on Intellia Therapeutics (NTLA – Research Report) and keeping the price ...